Compare FF & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FF | CRBP |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.3M | 184.4M |
| IPO Year | 2005 | 2014 |
| Metric | FF | CRBP |
|---|---|---|
| Price | $4.62 | $9.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 284.2K | ★ 449.5K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $3.09 | $7.12 |
| 52 Week High | $5.12 | $20.56 |
| Indicator | FF | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 51.86 |
| Support Level | $3.87 | $7.42 |
| Resistance Level | $4.69 | $9.57 |
| Average True Range (ATR) | 0.21 | 0.48 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 73.99 | 55.62 |
FutureFuel Corp makes and sells diversified chemical products, bio-based fuel products, and specialty chemical products. The company is organized into two segments based on product type: biofuels and chemicals. The biofuels segment sells biodiesel and other petroleum products, with fuels made from a mix of diesel, vegetable oils, and grease feedstock. The chemicals segment, which generates the majority of revenue, sells products used in the production of agricultural chemicals, including herbicides, as well as coatings and cleaning products such as detergents.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.